Price
Financials
Standalone, Rs crore| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 23.77 | 372.02 | 38.95 | 3.60 | 12.74 | 0.69 | 0.54 | 0.69 | 0.77 |
| Operating Profit | -23.77 | -372.02 | -38.95 | -3.60 | -12.74 | -0.69 | -0.54 | -0.69 | -0.77 |
| OPM % | |||||||||
| Other Income | 28.58 | 727.25 | 26.36 | -1.56 | 0.05 | 0.04 | -2.57 | 0.05 | 1.16 |
| Interest | 33.78 | 0.55 | 0.20 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 6.00 | 19.31 | 5.12 | 3.56 | 3.56 | 3.07 | 0.10 | 0.10 | 0.00 |
| Profit before tax | -34.97 | 335.37 | -17.91 | -8.74 | -16.25 | -3.72 | -3.21 | -0.74 | 0.39 |
| Tax % | 0.17% | 0.11% | 3.18% | 0.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -35.03 | 335.00 | -18.48 | -8.75 | -16.25 | -3.72 | -3.21 | -0.75 | 0.39 |
| EPS in Rs | |||||||||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | % | ||
| Compounded Profit Growth | % | 15% | 36% | 141% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | % | % | 3% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
| Reserves | -296.97 | 38.03 | 19.58 | 10.83 | -5.42 | -9.14 | -12.35 | -17.43 | -17.05 |
| Borrowings | 383.97 | 22.64 | 5.18 | 1.37 | 1.20 | 0.99 | 0.42 | 0.21 | 0.00 |
| Other Liabilities | 24.09 | 12.81 | 4.49 | 4.62 | 4.78 | 4.21 | 4.87 | 5.86 | 4.69 |
| Total Liabilities | 118.09 | 80.48 | 57.25 | 44.82 | 28.56 | 24.06 | 20.94 | 16.64 | 15.64 |
| Fixed Assets | 65.77 | 40.02 | 34.92 | 28.11 | 12.77 | 9.70 | 4.52 | 3.56 | 3.56 |
| CWIP | 10.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.53 | 0.53 | 0.08 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| Other Assets | 41.14 | 39.93 | 22.25 | 16.60 | 15.68 | 14.25 | 16.31 | 12.97 | 11.97 |
| Total Assets | 118.09 | 80.48 | 57.25 | 44.82 | 28.56 | 24.06 | 20.94 | 16.64 | 15.64 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 6.24 | 8.30 | -3.22 | 0.16 | 0.04 | 2.55 | -0.39 | 1.39 | |
| Cash from Investing Activity | -0.02 | 3.12 | -0.12 | 0.02 | 0.00 | 5.08 | 0.00 | 0.00 | |
| Cash from Financing Activity | -6.19 | -11.39 | 3.34 | -0.18 | 0.00 | -7.69 | 0.39 | -1.39 | |
| Net Cash Flow | 0.03 | 0.03 | 0.00 | 0.00 | 0.04 | -0.06 | 0.00 | 0.00 | |
| Free Cash Flow | 6.20 | 8.30 | -3.24 | 0.16 | 0.04 | 7.63 | -0.39 | 1.39 | |
| CFO/OP | -26% | -2% | 7% | -1% | -6% | -472% | 57% | -181% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | |||||||||
| Inventory Days | |||||||||
| Days Payable | |||||||||
| Cash Conversion Cycle | |||||||||
| Working Capital Days | |||||||||
| ROCE % | -11.69% | -29.41% | -7.10% | -50.80% | -17.05% | -3.34% | 2.85% |
Fundamentals
Market Cap₹ Cr.
Current Price₹
Book Value₹
ROCE2.85 %
ROE2.88 %
Dividend Yield%
Face Value₹ 10.0
Compounded Sales Growth (TTM)%
Compounded Profit Growth (TTM)141%
Standalone figures.
Profitability
ROE-5.72%
ROCE-5.51%
ROA-3.99%
ROE, 3-year average-14.09%
ROCE, 3-year average-13.48%
ROA, 3-year average-10.80%
ROE, 5-year average-23.09%
ROCE, 5-year average-22.00%
ROA, 5-year average-18.77%
ROIC (approx.)-6.87%
Other income / net worth0.47%
Per share
EPS (TTM)Rs -0.27
EPS (latest year)Rs -0.27
EPS, 3-year averageRs -0.91
EPS, 5-year averageRs -2.33
Book value per shareRs 3.77
Cash flow per shareRs -0.14
Free cash flow per shareRs 0.50
Leverage
Total debtRs 0 Cr
Cash and bankRs 0 Cr
Net debtRs 0 Cr
Debt to equity0.02x
Owners' fund to total sources63.52%
Debt to assets1.26%
Cash flow
Cash from Operating Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Free cash flow (latest year)Rs 1 Cr
FCFE (approx.: FCF + change in debt)Rs 1 Cr
Statement figures
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs -1 Cr
PBDT (TTM)Rs -1 Cr
Profit before tax (TTM)Rs -1 Cr
Net profit (TTM)Rs -1 Cr
Net profit (latest year)Rs -1 Cr
Depreciation (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 28 Cr
ReservesRs -17 Cr
Shareholders' fundsRs 11 Cr
Total assetsRs 17 Cr
Net blockRs 4 Cr
InvestmentsRs 0 Cr
ReceivablesRs 4 Cr
Other liabilitiesRs 6 Cr
Shares outstanding (crore)2.80
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 4 of 6| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Siris Ltd?
Siris Ltd (524746) has a market capitalisation of Rs Cr. at the close.